User Fees To Rise By 11 Percent For Drug Applications In Fiscal 2010
This article was originally published in The Pink Sheet Daily
FDA to collect $1.4 million for each application requiring clinical data; total of $569 million in fees for applications, establishments and products.
You may also be interested in...
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.